Article
Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate.
Bone marrow transplantation - 1 Apr 2006
Murphy N, Diviney M, Szer J, Bardy P, Grigg A, Hoyt R, King B, Macgregor L, Holdsworth R, McCluskey J, Tait B D
Abstract excerpt
Methotrexate (MTX), used as a graft-versus-host disease (GvHD) prophylactic agent in hematopoietic stem cell transplantation (HSCT), exerts its effect via folate cycle inhibition. A critical enzyme involved in folate metabolism is 5,10-methylenetetrahydrofolate reductase (MTHFR). We examined the association of a single nucleotide polymorphism (SNP) at position 677 in the MTHFR gene on GvHD outcomes in allogeneic...
Topics
- Adolescent
- Adult
- Aged
- Cohort Studies
- DNA
- Female
- Folic Acid
- Genotype
- Graft vs Host Disease
- Hematopoietic Stem Cell Transplantation
- Humans